Mechanically, our investigation into VEGF-C signaling and CD8+ T-cell dynamics provides clues on how MSI gastric cancers take advantage and refrain from rapid disease deterioration and immune evasion, offering potential therapeutic targets aimed at modulating lymphatic metastasis and enhancing anti-tumor immune responses. This evidence concerns the gene VEGFC and gastric cancer.